Mineralys Therapeutics, Inc. (MLYS)
After hours:
| Previous close | 12.80 |
| Open | 13.09 |
| Bid | 13.04 x 200 |
| Ask | 13.12 x 200 |
| Day's range | 12.73 - 13.23 |
| 52-week range | 5.85 - 17.70 |
| Volume | |
| Avg. volume | 169,522 |
| Market cap | 649.672M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.83 |
GlobeNewswireMineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024. Thursday, May 9th @ 8:30 a.m. ETDomestic:1-888-886-7786International
Insider MonkeyMineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript March 21, 2024 Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.85. MLYS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Mineralys Therapeutics Fourth […]
- GuruFocus.com
Mineralys Therapeutics Inc (MLYS) Reports Increased R&D Expenses Amid Progress in ...
MLYS Announces Financial Results for Q4 and Full Year 2023, with Key Clinical Milestones on Track
